Bruno Vincenzi

Summary

Publications

  1. ncbi request reprint Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
  2. ncbi request reprint COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters
    Giuseppe Perrone
    Surgical Pathology, Campus Bio Medico University, Via Emilio Longoni, Rome, 83 00155, Italy
    Virchows Arch 449:334-40. 2006
  3. doi request reprint The biological properties of cetuximab
    Bruno Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Alvaro del Portillo 200, Rome, Italy
    Crit Rev Oncol Hematol 68:93-106. 2008
  4. ncbi request reprint Cetuximab: from bench to bedside
    Bruno Vincenzi
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 10:80-95. 2010
  5. ncbi request reprint New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron
    Giuseppe Tonini
    University Campus Bio Medico, Medical Oncology, Via E Longoni 69, 00155, Rome, Italy
    Expert Opin Drug Metab Toxicol 1:143-9. 2005
  6. ncbi request reprint Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?
    Bruno Vincenzi
    Oncology Hematology Department, Campus Bio Medico University, Rome, Italy
    Med Hypotheses 61:98-101. 2003
  7. doi request reprint PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
    Bruno Vincenzi
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 227:927-33. 2012
  8. ncbi request reprint Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University, Rome, Italy
    Cancer 115:4849-56. 2009
  9. doi request reprint Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 223:384-8. 2010
  10. pmc Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    BMC Cancer 6:42. 2006

Detail Information

Publications105 found, 100 shown here

  1. ncbi request reprint Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
    ..Future clinical trials should be designed to prospectively evaluate the prognostic role of reduction of betaCTX and VEGF in response to ZOL to predict clinical and skeletal outcome...
  2. ncbi request reprint COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters
    Giuseppe Perrone
    Surgical Pathology, Campus Bio Medico University, Via Emilio Longoni, Rome, 83 00155, Italy
    Virchows Arch 449:334-40. 2006
    ..Furthermore, the high rate of COX-2 expression in the intestinal subtype of ampullary carcinoma may represent the rational for a histotype-tailored therapy targeting COX-2...
  3. doi request reprint The biological properties of cetuximab
    Bruno Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Alvaro del Portillo 200, Rome, Italy
    Crit Rev Oncol Hematol 68:93-106. 2008
    ..This paper will overview all the experimental and pre-clinical data on the biological properties of cetuximab...
  4. ncbi request reprint Cetuximab: from bench to bedside
    Bruno Vincenzi
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 10:80-95. 2010
    ..This review will illustrate pre-clinical and clinical data on biological properties of cetuximab focusing on the predictive markers of clinical response to this drug...
  5. ncbi request reprint New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron
    Giuseppe Tonini
    University Campus Bio Medico, Medical Oncology, Via E Longoni 69, 00155, Rome, Italy
    Expert Opin Drug Metab Toxicol 1:143-9. 2005
    ..Further studies incorporating dexamethasone to 5-HT(3) antagonists will be necessary to determine the relative efficacy of palonosetron compared with available agents. These trials could open a new era in the treatment of CINV...
  6. ncbi request reprint Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?
    Bruno Vincenzi
    Oncology Hematology Department, Campus Bio Medico University, Rome, Italy
    Med Hypotheses 61:98-101. 2003
    ....
  7. doi request reprint PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
    Bruno Vincenzi
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 227:927-33. 2012
    ..This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy...
  8. ncbi request reprint Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University, Rome, Italy
    Cancer 115:4849-56. 2009
    ..The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options...
  9. doi request reprint Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 223:384-8. 2010
    ..Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions...
  10. pmc Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    BMC Cancer 6:42. 2006
    ....
  11. ncbi request reprint Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni, 69, 00155, Rome, Italy
    Pharmacogenomics 8:319-27. 2007
    ....
  12. doi request reprint Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Medical Oncology, Università Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Support Care Cancer 21:1313-9. 2013
    ..Oxaliplatin-induced neuropathy is a dose-related side effect which occurs in almost 40 % of patients treated with oxaliplatin. Aim of the present study was to identify reliable clinical factors predicting its development and duration...
  13. ncbi request reprint Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Oncology 69:27-34. 2005
    ..The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients...
  14. doi request reprint A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Oncology 82:75-82. 2012
    ..This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients...
  15. doi request reprint Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
    Bruno Vincenzi
    Department of Medical Oncology, Laboratory Medicine, and Radiology, University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 14:4219-24. 2008
    ..We designed this trial to investigate if Mg(2+) serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan...
  16. ncbi request reprint Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
    Bruno Vincenzi
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Interferon Cytokine Res 25:144-51. 2005
    ....
  17. ncbi request reprint Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy
    Daniele Santini
    Medical Oncology Unit, University Campus Bio Medico, Rome, Italy
    Oncology 67:135-42. 2004
    ..We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy...
  18. ncbi request reprint Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Future Oncol 9:1809-11. 2013
    ..To our knowledge, this represents the first evidence of sunitinib activity in KIT wild-type melanoma. Further studies should be performed to confirm these preliminary data...
  19. doi request reprint Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience
    Bruno Vincenzi
    University Campus Bio Medico, Rome, Italy
    Expert Opin Investig Drugs 22:1-7. 2013
    ..To report on the anti-tumour activity and toxicity of sorafenib combined with dacarbazine in patients with pre-treated advanced soft tissue sarcoma (STSs)...
  20. doi request reprint Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival
    Sergio Morini
    Unit of Human Anatomy, CIR, Campus Bio Medico University of Rome, Rome, Italy
    Pancreas 42:60-6. 2013
    ..The objective of the study was to verify if histopathological differentiation of ampullary carcinoma after surgical resection may be related to survival...
  21. pmc Patterns of tumor response in canine and feline cancer patients treated with electrochemotherapy: preclinical data for the standardization of this treatment in pets and humans
    Enrico P Spugnini
    S A F U, Department, Regina Elena Cancer Institute, Rome, Italy
    J Transl Med 5:48. 2007
    ..Further studies on this topic are warranted in companion animals with spontaneous tumors to identify new molecular targets for electrochemotherapy and to the develop new therapeutical protocols to be translated to humans...
  22. ncbi request reprint MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients
    Francesco Pantano
    Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    Cancer Biol Ther 8:996-9. 2009
    ..The present study investigated the prognostic role of MUC2 and MUC5 apomucin expression in a series of surgically resected pancreatic cancer patients...
  23. ncbi request reprint Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas
    Enrico P Spugnini
    SAFU Department, Regina Elena Cancer Institute, Rome, Italy
    In Vivo 21:819-22. 2007
    ..Electrochemotherapy is well tolerated and has effectiveness against incompletely excised sarcomas in companion animals. Further investigations are warranted to improve the currently available protocols...
  24. doi request reprint Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer
    Bruno Vincenzi
    Division of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    Nat Clin Pract Oncol 5:455-65. 2008
    ..We discuss the rationale for tailoring anticancer treatment in patients with colorectal cancer according to individual molecular and clinical features, with the aim of improving response rates and reducing the incidence of toxic events...
  25. ncbi request reprint The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients
    Francesco Pantano
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    J Cell Mol Med 17:1415-21. 2013
    ..The M1 macrophage density and M1/M2 ratio, as confirmed in multivariate analysis, are factors that can help in predicting patients survival time after radical surgery for gastric cancer. ..
  26. ncbi request reprint Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6
    Giordano Dicuonzo
    Università Campus Bio Medico, Rome, Italy
    J Interferon Cytokine Res 23:649-54. 2003
    ..The sharp reduction in serum calcium levels observed in patients with fever may be related to zoledronic acid pharmacokinetic modifications...
  27. doi request reprint Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells
    Daniela Stoppoloni
    Department for the Development of Therapeutic Programs, Regina Elena Cancer Institute, Rome, Italy
    J Thorac Oncol 6:583-91. 2011
    ..The aim of this study was to investigate the expression and biological activity of aromatase (CYP19A1) in malignant mesothelioma (MM)...
  28. ncbi request reprint Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
    Daniele Santini
    Medical Oncolog, University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 13:4482-6. 2007
    ....
  29. ncbi request reprint Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis
    Bruno Vincenzi
    C I R, University Campus Bio Medico, Rome, Italy
    Oncol Rep 20:1213-20. 2008
    ..Hence, the present study contributes to clarify the controversial results on IL1beta polymorphisms and gastric cancer risk correlation evidencing the importance of ethnicity in the generation of the IL1beta polymorphism analysis...
  30. doi request reprint Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
    Daniele Santini
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    Lancet Oncol 13:1020-4. 2012
    ..We designed a pilot single-centre study to assess the effects of aprepitant-a neurokinin receptor inhibitor-for management of severe pruritus induced by biological drugs...
  31. pmc Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs
    Enrico P Spugnini
    SAFU Department, Regina Elena Cancer Institute, Rome, Italy
    J Transl Med 9:152. 2011
    ..In this article we evaluate the capability of ECT to allow the use of cisplatin despite its high toxicity in a spontaneous feline model of soft tissue sarcoma...
  32. doi request reprint Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Oncol Rep 25:1545-8. 2011
    ..This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients...
  33. ncbi request reprint Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model
    Enrico P Spugnini
    SAFU Department, Regina Elena Cancer Institute, Via delle Messi d oro, 156, 00158, Rome, Italy
    Cancer Chemother Pharmacol 59:375-81. 2007
    ..The results suggest that ECT is a well tolerated and potentially useful addition to surgery in controlling high-grade sarcomas. On the basis of these results, additional evaluations are warranted in pets and in humans...
  34. pmc Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    PLoS ONE 6:e19234. 2011
    ..RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG...
  35. ncbi request reprint An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    In Vivo 20:165-8. 2006
    ..After eleven months, the patient presented with signs of intestinal obstruction, requiring an ileocolic bypass. At definitive histological examination, the tumor exhibited features of mammary metastases...
  36. ncbi request reprint Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma
    Enrico P Spugnini
    SAFU Department, Regina Elena Cancer Institute, Rome, Italy
    Front Biosci (Elite Ed) 5:974-81. 2013
    ..The identification of effective combination coupled with the development of novel equipments and electrodes will be instrumental in planning the translation of these results to humans as per correct laboratory-clinical interface...
  37. doi request reprint Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting
    Daniele Santini
    Medical Oncology, University Hospital Campus Bio Medico, Rome, Italy
    Oncology 85:342-7. 2013
    ..Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer...
  38. doi request reprint Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis
    Daniela Stoppoloni
    Laboratory D, Department for the Development of Therapeutic Programs, Centro Ricerca Sperimentale, Regina Elena Cancer Institute, Rome, Italy
    Cancer 113:2761-9. 2008
    ..The human embryonic lethal abnormal vision (ELAV)-like protein HuR is a messenger RNA (mRNA)-binding protein that controls the stability of certain transcripts, including cyclooxygenase2 (COX-2)...
  39. ncbi request reprint 'Old' and 'new' drugs for the treatment of cancer pain
    Daniele Santini
    University Campus Bio Medico Roma, Oncologia Medica, Rome, Italy
    Expert Opin Pharmacother 14:425-33. 2013
    ....
  40. pmc Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    J Hematol Oncol 5:56. 2012
    ..These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker...
  41. doi request reprint Premetastatic niche: ready for new therapeutic interventions?
    Alice Zoccoli
    Campus Bio Medico University, Department of Medical Oncology, Rome, Italy
    Expert Opin Ther Targets 16:S119-29. 2012
    ..Sonic Hedgehog (SHH), FOXM1 and Notch pathways and signaling molecules such as integrin and chemokine could dictate their fate...
  42. doi request reprint Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
    Cristina Raimondi
    Division of Medical Oncology, Sapienza University of Rome, Rome, Italy
    Breast Cancer Res Treat 130:449-55. 2011
    ..The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer...
  43. doi request reprint In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Cancer Immunol Immunother 58:31-8. 2009
    ..The aim of our study was to evaluate the immunomodulating properties of a single-dose of zoledronic acid (ZA) on gammadelta T cells in a select group of disease-free breast cancer patients with osteopenia...
  44. ncbi request reprint A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid
    Carlo C Quattrocchi
    Department of Radiology, Centro Interdisciplinare per la Ricerca Bio Medica, Via Longoni 47, 00155, Rome, Italy
    Skeletal Radiol 36:1121-7. 2007
    ..The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months...
  45. ncbi request reprint Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma
    Paolo Magistrelli
    Department of Surgery, Catholic University School of Medicine, Rome, Italy
    J Cell Biochem 97:98-108. 2006
    ..The contemporary overexpression of Bax and Bcl-2 represents the strongest prognostic factor...
  46. doi request reprint Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Rome, Italy
    Expert Opin Biol Ther 9:945-9. 2009
    ..The aim of this study was to evaluate the effect of cigarette smoking on cetuximab efficacy in advanced colorectal cancer patients...
  47. ncbi request reprint Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 11:123-9. 2011
    ..The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy...
  48. pmc Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  49. ncbi request reprint Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Nat Clin Pract Oncol 3:325-38. 2006
    ..We briefly discuss identification of new molecular targets of bisphosphonates from genomic and proteomic analysis, and highlight the cellular consequences of drug-related enzyme inhibition...
  50. ncbi request reprint Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
    Domenico Borzomati
    Department of General Surgery, Campus Bio Medico University, Catholic University, Rome, Italy
    Hepatogastroenterology 52:780-4. 2005
    ..benign post-attinic lesion). In the present article we review this uncommon complication, discuss the technical surgical aspects associated with a very large perianal tissue removal, and data of the most recent literature in this field...
  51. doi request reprint Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated
    Domenico Borzomati
    Department of General Surgery, Campus Bio Medico University of Rome, Rome, Italy
    Updates Surg 65:121-4. 2013
    ..1 %). Bevacizumab may result in severe complications. Therefore, it is important to consider every patient treated with Bevacizumab at risk for life-threatening gastro-intestinal complications...
  52. doi request reprint The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen
    Bruno Vincenzi
    Department of Medical Oncology, University Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Support Care Cancer 20:135-9. 2012
    ..S-adenosylmethionine (AdoMet) administration is effective in the treatment of a variety of liver injuries, but it has never been evaluated in the prevention of chemotherapy-induced damage...
  53. ncbi request reprint Endocrine disruptors in utero cause ovarian damages linked to endometriosis
    Pietro G Signorile
    Fondazione Italiana Endometriosi, Rome, Italy
    Front Biosci (Elite Ed) 4:1724-30. 2012
    ..Considering the high incidence of endometriosis and of the premature ovarian failure associated to infertility in these patients, the data showed prompt a thoroughly reconsideration of the pathological framing of these lesions...
  54. doi request reprint PML down-regulation in soft tissue sarcomas
    Bruno Vincenzi
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 224:644-8. 2010
    ..Further investigations are needed to confirm these data and to assess the possible value of PML expression as a prognostic factor in these extremely aggressive diseases...
  55. doi request reprint New therapies in soft tissue sarcoma
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Alvaro del Portillo, 200, 00128, Rome, Italy
    Expert Opin Emerg Drugs 15:237-48. 2010
    ..Despite the efforts, overall 5-year survival rate in patients with soft tissue sarcomas of all stages remains only 50 - 60%...
  56. ncbi request reprint Antiangiogenic properties of metronomic chemotherapy in breast cancer
    Giuseppe Tonini
    Medical Oncology, University Campus Bio Medico, Rome, Via Emilio Longoni 83, 00155, Rome, Italy
    Future Oncol 3:183-90. 2007
    ..This review aims to explain the rationale behind metronomic and targeted therapies in breast cancer and to examine the main preclinical and clinical (neoadjuvant, adjuvant and advanced settings) studies conducted...
  57. ncbi request reprint A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Anticancer Res 25:669-74. 2005
    ..The purpose of this open-label, non randomized, pilot study was to assess the safety and efficacy of an intensive 19-day epoetin alfa treatment in anemic patients with solid tumors receiving chemotherapy...
  58. ncbi request reprint Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade
    Giuseppe Perrone
    Department of Surgical Pathology, Campus Bio Medico University, Rome, Italy
    Mod Pathol 20:344-51. 2007
    ..This suggests reelin may behave as a specific histological marker and may represent a useful biomarker to predict aggressive phenotypic behavior of prostatic cancer cells...
  59. ncbi request reprint The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni 69, 00155, Rome, Italy
    Expert Opin Emerg Drugs 11:665-83. 2006
    ..This clinical review focuses on the defining role of the two most clinically advanced novel agents, bevacizumab and cetuximab in metastatic colorectal cancer...
  60. ncbi request reprint Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors
    Enrico P Spugnini
    S A F U Department, Regina Elena Cancer Institute, Rome, Italy
    Anticancer Res 26:4585-9. 2006
    ..The purpose of this investigation was to assess the adjuvant potentials of ECT for the treatment of incompletely excised mast cell tumors (MCT)...
  61. ncbi request reprint Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities
    Daniele Santini
    Oncology Department, University Campus Bio Medico, Rome, Italy
    BioDrugs 18:269-78. 2004
    ....
  62. ncbi request reprint Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy
    Gaia Schiavon
    Medical Oncology and Haematology, Campus Bio Medico University, Via Emilio Longoni 83, IT 00155 Rome, Italy
    Chemotherapy 50:194-5. 2004
  63. pmc Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
    Bruno Vincenzi
    Department of Medical Oncology, Università Campus Bio Medico, Rome, Italy
    Clin Sarcoma Res 3:6. 2013
    ..We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS)...
  64. doi request reprint The role of bone microenvironment, vitamin D and calcium
    Daniele Santini
    University Campus Bio Medico, Via Alvaro del Portillo, Rome, Italy
    Recent Results Cancer Res 192:33-64. 2012
    ....
  65. doi request reprint Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Alvaro del Portillo, 200, Rome, Italy
    Expert Opin Investig Drugs 20:1685-705. 2011
    ..Therefore, the inhibition of mTOR via rapamycin, rapamycin analogs (rapalogs) and ATP-competitive inhibitors seems to be a promising path to follow for a fully tailored therapy...
  66. ncbi request reprint Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient
    Bruno Vincenzi
    University Campus Bio Medico, Rome, Italy
    J Clin Oncol 22:4649-51. 2004
  67. ncbi request reprint New targets, new drugs for metastatic bone pain: a new philosophy
    Francesco Pantano
    University Campus Bio Medico, Medical Oncology, Rome, Italy
    Expert Opin Emerg Drugs 16:403-5. 2011
    ..Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management...
  68. doi request reprint Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
    Angela Gradilone
    Department of Molecular Medicine, Sapienza University, Viale Regina Elena, Rome, Italy
    J Cell Mol Med 15:1066-70. 2011
    ..Thus, there is an urgent need to improve detection methods to identify CTC which undergone epithelial mesenchymal transition program...
  69. doi request reprint Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 226:780-4. 2011
    ..These data highlight the central role of RANK/RANKL/OPG pathway as potential therapeutic target not only in bone metastasis management, but also in the adjuvant setting...
  70. doi request reprint Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo)
    Stefania Meschini
    Department of Technology and Health, Italian National Institute of Health, Rome, Italy
    Eur J Cancer 48:2236-43. 2012
    ....
  71. ncbi request reprint Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients
    Daniele Santini
    University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 11:3784-9. 2005
    ....
  72. ncbi request reprint Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma
    Enrico P Spugnini
    SAFU Department, CRS, Regina Elena Cancer Institute, Rome, Italy
    Clin Cancer Res 12:6133-43. 2006
    ..The aim of the present study was to evaluate the effects of piroxicam, a widely used nonsteroidal anti-inflammatory drug, alone and in combination with cisplatin (CDDP), on cell growth of mesothelioma cells...
  73. ncbi request reprint Molecular prognostic factors in patients with pancreatic cancer
    Giuseppe Tonini
    Campus Bio Medico University, Medical Oncology, Via Emilio Longoni, 83, 00155, Rome, Italy
    Expert Opin Ther Targets 11:1553-69. 2007
    ..The markers with the strongest evidence as independent predictors of patient outcome include, p16, MMP7 and vascular endothelial growth factor...
  74. ncbi request reprint Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study
    Vincenzo Bianco
    U O Clinical Oncology, Policlinico Umberto I, Department of Experimental Medicine, University of Rome La Sapienza, Rome, Italy
    Anticancer Res 22:3053-6. 2002
    ..Recently, new active drugs with lesser toxicity have became widely used in this setting. In this prospective study we evaluated the efficacy and tolerability of gemcitabine in elderly patients with stages III-IV NSCLC...
  75. ncbi request reprint Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy
    Giuseppe Tonini
    Università Campus Bio Medico, Rome, Italy and Regina Elena Cancer Institute, Rome, Italy
    J Clin Oncol 21:2215-6. 2003
  76. doi request reprint High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
    Daniele Santini
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    Oncologist 13:1270-5. 2008
    ..Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases...
  77. ncbi request reprint S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury
    Daniele Santini
    Medical Oncology, Center for Biomedical Research CIR, Laboratory of Internal Medicine and Hepatology, Campus Bio Medico University, Rome, Italy
    Anticancer Res 23:5173-9. 2003
    ..Our study was aimed at assessing the protective effect of AdoMet supplementation in cancer chemotherapy-induced liver toxicity...
  78. ncbi request reprint Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma
    Enrico P Spugnini
    SAFU Department, Regina Elena Cancer Institute, Rome, Italy
    Melanoma Res 16:23-7. 2006
    ..Further studies are needed to characterize this approach and to determine its suitability for head and neck mucosal melanoma...
  79. ncbi request reprint Liver harvesting surgical technique for the treatment of retro-hepatic caval thrombosis concomitant to renal cell carcinoma: perioperative and long-term results in 15 patients without mortality
    Michele Gallucci
    Department of Urology, Regina Elena Institute, Rome, Italy
    Eur Urol 45:194-202. 2004
    ..In the presence of retro-hepatic IVC thrombosis, this technique improves vascular control and allows to perform a large cavotomy with an en-bloc removal of the thrombus and the tumor...
  80. doi request reprint NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population
    Silvia Angeletti
    Clinical Pathology, University Campus Bio Medico, Rome, Italy
    Hum Immunol 70:729-32. 2009
    ..Meta-analyses of these SNPs and further analyses of additional polymorphisms/haplotypes in NOD genes will help determine their role in carcinogenesis...
  81. pmc First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab
    Giuseppe Tonini
    Medical Oncology, University Campus, Bio Medico, Rome, Italy
    Onco Targets Ther 2:73-82. 2009
    ..In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit, and the role of cetuximab in first-line treatment of metastatic CRC...
  82. pmc Targeting bone metastases starting from the preneoplastic niche: home sweet home
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Breast Cancer Res 13:111. 2011
    ....
  83. ncbi request reprint Azygo-tracheal fistula in a complete implantable central venous system
    Carlo Cosimo Quattrocchi
    Interdisciplinary Center for Biomedical Research, Department of Radiology, University Campus Bio Medico of Rome, Via Longoni, Rome, Italy
    J Clin Oncol 24:4029-31. 2006
  84. ncbi request reprint Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome
    Recent Pat Anticancer Drug Discov 1:383-96. 2006
    ..The translation into the clinical setting of the preclinical evidence of an antiangiogenic power of these drugs is becoming an imperative need and should represent the objective of future clinical trials...
  85. ncbi request reprint Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
    Daniele Santini
    Università Campus Bio Medico, 00155 Rome, Italy
    Clin Cancer Res 8:1080-4. 2002
    ..The purpose of this study was to evaluate the modifications in angiogenic cytokines levels after pamidronate infusion. EXPERIMENTAl..
  86. ncbi request reprint Emerging anti-cancer molecular mechanisms of aminobisphosphonates
    Michele Caraglia
    Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours, Fondazione G Pascale, Via Mariano Semmola, 80131 Naples, Italy
    Endocr Relat Cancer 13:7-26. 2006
    ..To date, however, the real molecular targets of NBPs are not completely known and new technological platforms are required in order to detect them and to develop new anti-cancer strategies based on the use of NBPs...
  87. ncbi request reprint Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
    Daniele Santini
    Medical Oncology, Department of Laboratory Medicine, Campus Bio Medico University, 00155 Rome, Italy
    Clin Cancer Res 9:2893-7. 2003
    ..The patients were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) just before and at 1, 2, 7, and 21 days after zoledronic acid infusion...
  88. ncbi request reprint Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma
    Bruno Vincenzi
    Cancer 100:1987-8; author reply 1988. 2004
  89. ncbi request reprint Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium
    Bruno Vincenzi
    Expert Opin Pharmacother 9:1267-9. 2008
    ..Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab, by the inhibition of epidermal growth factor (EGR), is able to induce hypomagnesaemia by interfering with magnesium transport in the kidney...
  90. doi request reprint Survey on learning needs and preferred sources of information to meet these needs in Italian oncology patients receiving chemotherapy
    Michela Piredda
    Università Campus Bio Medico di Roma, Via Alvaro del Portillo, 220 00128 Roma, Italy
    Eur J Oncol Nurs 12:120-6. 2008
    ..In order to meet cancer patients' information needs, health professionals' education and practice should be improved...
  91. ncbi request reprint Predictive factors for response to chemotherapy in colorectal cancer patients
    Bruno Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Emilio Longoni, 69, 00155 Rome, Italy
    Crit Rev Oncol Hematol 52:45-60. 2004
    ..The results of this review provide the rationale basis for personalizing anticancer treatment in colorectal cancer patients by molecular and clinical features, aiming to improve response rate and reduce toxicities...
  92. ncbi request reprint Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors
    Cristian Massacesi
    Medical Oncology, Oncology and Radiotherapy Department of Ancona, Ancona, Italy
    Anticancer Drugs 14:533-41. 2003
    ..Predictive and protective factors listed above could assist the management of this toxicity that has probably been underestimated until now...
  93. ncbi request reprint Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence
    Antonio Russo
    Universita di Palermo, Section of Medical Oncology, Department of Surgical and Oncological Sciences, Italy
    Expert Opin Ther Targets 11:1571-86. 2007
    ....
  94. ncbi request reprint Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer
    Daniele Santini
    Clin Cancer Res 9:3215; author reply 3216. 2003
  95. ncbi request reprint Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report
    Raffaele Addeo
    UOC Oncologia, S Giovanni di Dio Hospital, ASL Napoli3 Via Giovanni XXIII 80020 Frattaminore, Naples, Italy
    Support Care Cancer 16:209-14. 2008
    ..We studied the safety and the effect of a new bisphosphonate, zoledronic acid (ZA), on pain and on quality of life (QoL) in elderly patients with bone metastases...
  96. ncbi request reprint European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006
    Gaia Schiavon
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni, 47, 00155 Rome, Italy
    Expert Opin Biol Ther 7:269-78. 2007
    ....
  97. ncbi request reprint Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient
    Giuseppe Tonini
    J Natl Cancer Inst 97:606-7. 2005
  98. ncbi request reprint New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor
    Bruno Vincenzi
    J Clin Oncol 24:1957; author reply 1957-8. 2006
  99. ncbi request reprint Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Via Emilio Longoni, 69, 00155 Rome, Italy
    Cancer Chemother Pharmacol 59:613-20. 2007
    ..The aim of the present study was to define the feasibility and efficacy of XELOX administered through a new chronomodulated schedule in untreated advanced colorectal cancer (CRC) patients...
  100. ncbi request reprint Thymidylate synthase expression in colorectal cancer: the never-ending story
    Bruno Vincenzi
    J Clin Oncol 23:2108; author reply 2108-9. 2005
  101. ncbi request reprint Chemotherapy-induced steatohepatitis in colorectal cancer patients
    Umberto Vespasiani Gentilucci
    J Clin Oncol 24:5467; author reply 5467-8. 2006